Loading cancer entity…
Loading cancer entity…
Clinical trials
1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00278382 | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00016094 | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2013 | clinicaltrials |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00089271 | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098891 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005982 | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006473 | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005080 | 506U78 in Treating Patients With Lymphoma | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00003613 | O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00891072 | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00412997 | LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma | completed | Phase 1 | 14 | NovartisINDUSTRY | 1 | Nov 27, 2012 | clinicaltrials |
| NCT00699296 | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | terminated | Phase 2 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 27, 2012 | clinicaltrials |
| NCT00061048 | Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00168064 | Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides | completed | Phase 2 | 260 | Yaupon TherapeuticsINDUSTRY | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00742495 | Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.(BCX1777-108) | terminated | Phase 1 / Phase 2 | 2 | Mundipharma Research LimitedINDUSTRY | 6 | Oct 24, 2012 | clinicaltrials |
| NCT00355472 | Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL | completed | Phase 1 | 16 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Oct 18, 2012 | clinicaltrials |
| NCT00969085 | Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
| NCT01036399 | Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients | terminated | Phase 2 | 9 | University of BolognaOTHER | 1 | Aug 27, 2012 | clinicaltrials |
| NCT00748319 | Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma(KIR) | completed | N/A | 495 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 22, 2012 | clinicaltrials |
| NCT00535470 | An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides | completed | Phase 2 | 100 | Yaupon TherapeuticsINDUSTRY | 1 | Aug 9, 2012 | clinicaltrials |
| NCT01341119 | Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma | completed | — | 40 | Samsung Medical CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00127881 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | terminated | Phase 3 | 76 | Emergent Product Development Seattle LLCINDUSTRY | 5 | Jul 26, 2012 | clinicaltrials |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jul 9, 2012 | clinicaltrials |
| NCT00725231 | Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP(A-CHOP-14) | unknown | Phase 3 | 274 | University of GöttingenOTHER | 1 | May 7, 2012 | clinicaltrials |
| NCT00704691 | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas | terminated | Early Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT01470066 | Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas | unknown | — | 80 | Chonnam National University HospitalOTHER | 1 | Nov 11, 2011 | clinicaltrials |
| NCT01467024 | Evaluation of the MP Diagnostics HTLV Blot 2.4 | unknown | — | 600 | MP Biomedicals, LLCINDUSTRY | 1 | Nov 8, 2011 | clinicaltrials |
| NCT00930605 | The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)(C+CHOP/ESHAP) | completed | Phase 2 | 16 | King Chulalongkorn Memorial HospitalOTHER | 1 | Oct 6, 2011 | clinicaltrials |
| NCT00791947 | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | completed | Phase 2 | 166 | University of AarhusOTHER | 3 | Sep 8, 2011 | clinicaltrials |
| NCT01418430 | Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) | completed | Phase 4 | — | King's College Hospital NHS TrustOTHER | 1 | Aug 22, 2011 | clinicaltrials |
| NCT00880867 | Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma | terminated | Phase 1 | 3 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT00840385 | Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)(FAD) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Sep 15, 2010 | clinicaltrials |
| NCT00974324 | Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma(PTCL) | unknown | Phase 2 | 15 | Fudan UniversityOTHER | 1 | Sep 15, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT01132989 | Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma(REvMM2009) | unknown | Phase 2 | 10 | Florida Academic Dermatology CentersOTHER | 1 | May 28, 2010 | clinicaltrials |
| NCT00161239 | LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma | terminated | N/A | 64 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00418535 | Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma | completed | Phase 2 | — | Samsung Medical CenterOTHER | 1 | Oct 21, 2009 | clinicaltrials |
| NCT00374699 | Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | Samsung Medical CenterOTHER | 1 | Oct 14, 2009 | clinicaltrials |
| NCT00970385 | Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma(LTP) | completed | Phase 3 | 95 | University Hospital, GrenobleOTHER | 1 | Sep 9, 2009 | clinicaltrials |
| NCT00441025 | The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL | terminated | Phase 2 | 4 | Mahidol UniversityOTHER | 1 | Jun 25, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00779896 | Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study | unknown | Phase 1 / Phase 2 | 15 | McGill UniversityOTHER | 1 | Oct 24, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Feb 7, 2013source: clinicaltrials